Level C· Early human research exploring benefitsProspective StudyEurope PMCOpen access

Lack of p38 activation in T cells increases IL-35 and protects against obesity by promoting thermogenesis

Nikolic I., Ruiz-Garrido I., Crespo M., Romero-Becerra R., Leiva-Vega L., Mora A.

Prospective Study, published in EMBO Rep (2024) — summary generated from the PubMed abstract.

Open my reading list
Level C· Early human research exploring benefitsEvidence level of this study

Early human evidence such as case series or small samples is exploring possible benefits.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Prospective Study
Journal
EMBO Rep (2024)
Reported sample size
—
Source database
Europe PMC
PMID
38730210
PMCID
PMC11169359
DOI
10.1038/s44319-024-00149-y
Citations
4

Abstract (original English)

Obesity is characterized by low-grade inflammation, energy imbalance and impaired thermogenesis. The role of regulatory T cells (Treg) in inflammation-mediated maladaptive thermogenesis is not well established. Here, we find that the p38 pathway is a key regulator of T cell-mediated adipose tissue (AT) inflammation and browning. Mice with T cells specifically lacking the p38 activators MKK3/6 are protected against diet-induced obesity, leading to an improved metabolic profile, increased browning, and enhanced thermogenesis. We identify IL-35 as a driver of adipocyte thermogenic program through the ATF2/UCP1/FGF21 pathway. IL-35 limits CD8 + T cell infiltration and inflammation in AT. Interestingly, we find that IL-35 levels are reduced in visceral fat from obese patients. Mechanistically, we demonstrate that p38 controls the expression of IL-35 in human and mouse Treg cells through mTOR pathway activation. Our findings highlight p38 signaling as a molecular orchestrator of AT T cell accumulation and function.

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Early human evidence such as case series or small samples is exploring possible benefits.

How we grade evidence
CD8-Positive T-LymphocytesAnimalsMice, Inbred C57BLMice, KnockoutHumansMiceObesityInflammationp38 Mitogen-Activated Protein KinasesInterleukins

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.